Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.
Revenue of Vaxxinity, Inc. (VAXX)
Revenue in 2023 (TTM): $
According to Vaxxinity, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Vaxxinity, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-2,234,000 | $-56,051 | $-56,934 | $-56,934 |
| 2022 | $ | $-1,684,000 | $-73,036,000 | $-75,222,000 | $-75,210,000 |
| 2021 | $66 K | $-1,871,000 | $-123,964,000 | $-137,175,000 | $-138,015,000 |
| 2020 | $557 K | $505 K | $-37,326,000 | $-39,957,000 | $-35,377,000 |
| 2019 | $ | $-107,000 | $-13,581,000 | $-14,163,000 | $-14,219,000 |